Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 13.66 CNY [4][12]. Core Views - The company's performance in the first half of 2025 was under pressure, with a revenue of 1.265 billion CNY, a year-on-year decrease of 24.71%, and a net profit of 144 million CNY, down 29.71% [1][2]. - The pharmaceutical industrial sector is facing short-term challenges, but marketing reforms and new product development are expected to support long-term growth [2][3]. - The company is advancing its research projects, particularly in the stem cell drug market, which shows significant potential [3]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 1.265 billion CNY, a decrease of 24.71% year-on-year, and a net profit of 144 million CNY, down 29.71% [1]. - The second quarter of 2025 saw a revenue of 459 million CNY, a decline of 23.52%, and a net profit of 27 million CNY, down 54.58% [1]. Business Segments - The pharmaceutical industrial segment generated 1.229 billion CNY in revenue, down 25.06%, while the pharmaceutical commercial segment brought in 33 million CNY, down 3.12% [2]. - The OTC series revenue was 583 million CNY, a decrease of 36.05%, and the prescription drug series revenue was 636 million CNY, down 10.67% [2]. Marketing and R&D Initiatives - The company is implementing marketing reforms, including optimizing pricing policies and enhancing online and offline collaboration [2]. - Several R&D projects are progressing, including clinical trials for stem cell treatments, which are expected to contribute to long-term growth [3]. Future Projections - Revenue projections for 2025-2027 are estimated at 2.417 billion CNY, 2.629 billion CNY, and 2.887 billion CNY, respectively, with corresponding net profits of 224 million CNY, 292 million CNY, and 366 million CNY [8][10]. - The company anticipates a gradual recovery starting in 2026, with expected growth rates of 1.9%, 8.8%, and 9.8% for revenue [10][12].

Core Viewpoint - The company Jiuzhitang is advancing its research in stem cell therapy, particularly focusing on a new drug for treating Autism Spectrum Disorder (ASD) using human bone marrow mesenchymal stem cells, marking a significant milestone in clinical trials in China [1][2]. Group 1: Clinical Trial Developments - Jiuzhitang's subsidiary, Beijing Meike, has received ethical approval to initiate clinical trials for its human bone marrow mesenchymal stem cell injection project, specifically targeting ASD [1][2]. - The clinical trial for the stem cell injection has been approved by the National Medical Products Administration, making it the first of its kind in China for treating ASD [2]. Group 2: Product and Market Potential - The human bone marrow mesenchymal stem cell injection is classified as a Class 1 new drug and is aimed at treating Autism Spectrum Disorder, a complex neurodevelopmental disorder with no approved medications in China [2]. - Jiuzhitang is also making progress in other projects, including YB209, an innovative anticoagulant drug, and YB211, a new antibiotic targeting drug-resistant bacterial infections, both of which show promising market potential [3]. Group 3: Infrastructure and Recognition - Beijing Meike has established a large-scale stem cell drug research and production facility that meets GMP standards in China, the US, and the EU, positioning itself as a leading enterprise in the stem cell field in China [4].

Company Overview - JiuZhiTang Co., Ltd. is located in Beijing and Changsha, established on May 12, 1999, and listed on June 28, 2000. The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs [2][3] - The revenue composition includes prescription drugs (50.27%), OTC products (46.11%), other products (2.50%), health products (0.92%), and other supplementary products (0.20%) [2] Financial Performance - For the first half of 2025, JiuZhiTang reported revenue of 1.265 billion yuan, a year-on-year decrease of 24.71%, and a net profit attributable to shareholders of 144 million yuan, down 29.71% year-on-year [2] - The company has distributed a total of 4.364 billion yuan in dividends since its A-share listing, with 935 million yuan distributed over the past three years [3] Stock Performance - As of August 27, JiuZhiTang's stock price was 12.00 yuan per share, with a market capitalization of 10.271 billion yuan. The stock has increased by 56.60% year-to-date [1] - The stock has seen a net outflow of 22.5743 million yuan in major funds, with significant trading activity reflected in the recent five-day (1.44% increase), twenty-day (5.36% increase), and sixty-day (16.62% increase) performance [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.14% to 50,500, with an average of 13,739 circulating shares per shareholder, a decrease of 20.09% [2][3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Stable Growth Mixed Fund, holding 1.996 million shares [3]

Investment Rating - The report maintains a "Positive" investment rating for the stem cell therapy industry [12]. Core Insights - Stem cell therapy is accelerating from theory to clinical application, with mesenchymal stem cells (MSC) becoming the mainstream due to their application advantages. Over ten products have been approved globally, covering various fields such as cardiovascular, metabolic, and neurological diseases. The approval of the first "off-the-shelf" MSC therapy by the FDA in late 2024 and the first MSC drug in China in early 2025 marks a significant milestone in the industry [3][7][8]. Summary by Sections Industry Overview - Stem cells, known for their self-renewal and multi-directional differentiation capabilities, have evolved since their concept was introduced in the 19th century. MSCs have become the primary focus in clinical research and application due to their broad application advantages. The global stem cell therapy market is rapidly advancing, with numerous products approved for various indications [7][20]. Regulatory Milestones - The FDA's approval of the first "off-the-shelf" MSC therapy in late 2024, which demonstrated a 70.4% objective response rate by day 28 and a 68.5% overall survival rate by day 180, sets a precedent for the industry. Concurrently, the approval of "Aimi Maitosai" in China in early 2025 signifies the recognition of stem cell therapy in regulatory and clinical practices [8][45]. Company Spotlight: Jiuzhitang - Jiuzhitang has established a comprehensive stem cell research and industrialization platform, leading in clinical trials in China. Its core product, itMSC, has shown promising results in I/II phase clinical trials for ischemic stroke in the U.S., with significant improvements in patient outcomes. The company is also exploring other indications such as aPAP and AD, indicating a broad potential market [9][67]. Market Potential and Applications - The MSC therapy market is expanding into various fields, including cardiovascular, immune, and metabolic diseases. Companies are actively exploring applications in these areas, with early research showing potential benefits in diabetes and IBD, although further validation is needed [10][30][47]. Clinical Development - The report highlights the ongoing clinical trials for various MSC products targeting conditions like ischemic stroke and aPAP. Jiuzhitang's itMSC is in advanced clinical stages, with promising safety and efficacy data, suggesting a strong potential for long-term patient benefits [64][66].

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-064 九芝堂股份有限公司 关于并购基金存续期限延长的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 2025 年 8 月 26 日，九芝堂股份有限公司（以下简称"公司"）第九届董事 会第十次会议审议通过《关于并购基金存续期限变更的议案》，公司控股子公司 珠海横琴九芝堂雍和启航股权投资基金（有限合伙）（以下简称"并购基金"） 存续期限即将到期，同意将其存续期限延长 15 年，并购基金存续期延至 2040 年 9 月 5 日。具体情况如下： 一、并购基金基存续期限延长的情况 珠海横琴九芝堂雍和启航股权投资基金（有限合伙）成立于 2017 年 9 月 6 日，成立后主要聚焦于干细胞产业方向的投资，发起设立了九芝堂美科（北京） 细胞技术有限公司和投资 Stemedica Cell Technologies, Inc.。截至目前，并 购基金投资的项目处在干细胞研发和临床阶段。 二、并购基金存续期限延长对公司的影响 本次并购基金存续期限延长符合并购基金的实际运作情况，有利于保证并购 基金的良好 ...

临时公告 证券代码：000989 证券简称：九芝堂 公告编号：2025-062 九芝堂股份有限公司 关于控股子公司研发新药启动临床试验的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 2025 年 3 月 12 日，九芝堂股份有限公司（以下简称"公司"）发布《关于 控股子公司研发新药获得临床试验批准的公告》，公司控股子公司九芝堂美科（北 京）细胞技术有限公司（以下简称"北京美科"）研发的新药人骨髓间充质干细 胞注射液近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》， 同意开展治疗孤独症的临床试验。具体信息详见公司于 2025 年 3 月 12 日发布在 《中国证券报》《证券时报》《证券日报》《上海证券报》及巨潮资讯网的相关 公告。 近日，上述研究项目在临床试验牵头单位首都医科大学附属北京安定医院通 过伦理委员会审查。北京美科与北京安定医院认为已经具备启动临床试验的条件， 于 2025 年 8 月 26 日召开临床试验启动会。现将主要相关情况公告如下： 一、临床试验项目情况 1、本项临床试验用药品为人骨髓间充质干细胞（hBMMSC ...

公告文件 二、董事会会议审议情况 证券代码：000989 证券简称：九芝堂 公告编号：2025-063 九芝堂股份有限公司 第九届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 一、董事会会议召开情况 九芝堂股份有限公司第九届董事会第十次会议通知于 2025 年 8 月 22 日以电 子邮件方式发出，会议于 2025 年 8 月 26 日以通讯方式召开。会议应出席董事 9 名，实际出席董事 9 名。本次董事会会议的召开符合有关法律、行政法规、部门 规章、规范性文件和公司章程的规定。 在公司董事充分理解会议议案并表达意见后，本次会议一致审议通过了以下 议案： 关于并购基金存续期限变更的议案 公司控股子公司珠海横琴九芝堂雍和启航股权投资基金（有限合伙）（以下 简称"并购基金"）存续期限即将到期，现将其存续期限延长15年，并购基金存 续期延至2040年9月5日。详细内容请参看公告在《中国证券报》《证券时报》《证 券日报》《上海证券报》及巨潮资讯网的《关于并购基金存续期限变更的公告》 （公告编号：2025-064）。 表决情况：同意 9 票， ...

Market Overview - As of August 26, the Shanghai Composite Index fell by 0.39% to 3868.3820 points, while the Shenzhen Component Index rose by 0.26% to 12473.174 points [1] Top Gainers in Hunan Stocks - Topvi Information opened at 37.290 and closed at 40.270, achieving a daily increase of 10.00% with a trading volume of 1,329,989 lots [2] - Youa Shares opened at 7.020 and closed at 7.610, marking a rise of 5.84% and a trading volume of 2,169,265 lots [2] - ST Jiajia opened at 6.590 and closed at 6.860, with a daily increase of 5.05% and a trading volume of 106,992 lots [2] - Yuhuan CNC opened at 22.430 and closed at 23.620, reflecting a rise of 4.79% with a trading volume of 155,652 lots [2] - Jiugui Liquor opened at 66.500 and closed at 69.400, increasing by 3.37% with a trading volume of 447,908 lots [2] Top Losers in Hunan Stocks - Hengli Tui opened at 0.160 and closed at 0.150, experiencing a decline of 11.76% with a trading volume of 611,606 lots [3] - Jiu Zhi Tang (Rights Protection) opened at 12.460 and closed at 12.250, down by 3.62% with a trading volume of 526,762 lots [3] - *ST Biology (Rights Protection) opened at 9.770 and closed at 9.450, decreasing by 3.57% with a trading volume of 91,325 lots [3] - Changlan Technology opened at 19.200 and closed at 18.820, falling by 3.14% with a trading volume of 97,154 lots [3] - Shanhe Intelligent opened at 16.660 and closed at 16.220, down by 2.64% with a trading volume of 1,057,297 lots [3]

Investment Rating - The investment rating for the industry is "Positive" and is maintained [8]. Core Insights - The innovation layout of traditional Chinese medicine (TCM) companies includes two main categories: (1) TCM new drugs primarily classified as Class 1, which cannot currently use the same valuation system as innovative drugs due to differences in input-output, release rhythm, and lifecycle; (2) Innovative chemical and biological drugs, which are in need of value reassessment within TCM companies [2][6]. - The approval of TCM new drugs is accelerating, but the industry is still in its early development stage. From 2017 to 2024, the approval of TCM new drugs shows an accelerating trend, and with the implementation of policies and active corporate layouts, a surge in TCM new drug listings is expected [6][17]. - Several TCM companies are actively laying out innovative chemical and biological drugs, with companies like Jiuzi Tang, Kangyuan Pharmaceutical, Yiling Pharmaceutical, and Tianshili having multiple pipelines entering clinical stages, laying a solid foundation for long-term development [6][21]. Summary by Sections TCM New Drug Approval - The approval of TCM new drugs is showing an accelerating trend, indicating a potential future surge in listings due to supportive policies and active corporate strategies [6][17]. - The industry is still considered to be in its early development stage, with a different valuation system compared to chemical and biological drugs [6][17]. Innovative Drug Layout of TCM Companies - TCM companies are increasingly involved in the layout of innovative chemical and biological drugs, with several companies having multiple pipelines in clinical stages [21][22]. - Specific companies such as Jiuzi Tang focus on stem cell drugs, while Kangyuan Pharmaceutical has several pipelines in late-stage clinical trials for major diseases [21][22]. - Yiling Pharmaceutical has innovative chemical drugs entering the harvest stage, and Tianshili is involved in various fields including dual antibodies and stem cell injections [21][22]. Investment Perspective - The report suggests that the "insurance fund's transformation" will continue to evolve, with innovative drugs being a primary investment focus. Companies with healthy cash flow and innovative capabilities are favored [28]. - The report emphasizes the importance of breakthrough therapies and technological advancements, particularly in new treatment areas such as cytokine immunotherapy and PD1-based therapies [28].

Market Performance - The Chinese medicine sector rose by 0.47% on August 25, with Tianmu Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] Top Gainers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.80, up 10.00% with a trading volume of 144,000 shares and a transaction value of 271 million [1] - Jizhitang (000989) closed at 12.71, up 8.08% with a trading volume of 895,100 shares [1] - Zhendong Pharmaceutical (300158) closed at 66.80, up 7.28% with a trading volume of 1,339,500 shares [1] - Enwei Pharmaceutical (301331) closed at 39.08, up 6.95% with a trading volume of 40,600 shares [1] - New Great Pharmaceutical (002873) closed at 13.31, up 6.06% with a trading volume of 537,200 shares [1] Decliners in Chinese Medicine Sector - Jichuan Pharmaceutical (600566) closed at 26.57, down 3.45% with a trading volume of 277,600 shares [2] - ST Xiangxue (300147) closed at 10.44, down 2.79% with a trading volume of 356,600 shares [2] - Lingrui Pharmaceutical (600285) closed at 23.68, down 1.82% with a trading volume of 170,300 shares [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 334 million from institutional investors, while retail investors saw a net inflow of 164 million [2][3] - Major stocks like Jizhitang and Tianmu Pharmaceutical had significant net inflows from retail investors, while institutional investors showed mixed interest [3]